[1] Weintraub RG, Semsarian C, Macdonald P. Dilated cardiomyopathy[J]. Lancet, 2017, 390(10092): 400-414. DOI: 10.1016/S0140-6736(16)31713-5.
[2] 中华医学会心血管病学分会,中国心肌炎心肌病协作组. 中国扩张型心肌病诊断和治疗指南[J]. 临床心血管病杂志,2018,34(5):421-434. DOI:10.13201/j.issn.1001-1439. 2018.05.001.
[3] Hussain S, Haroon J, Ejaz S, et al. Variants of resistin gene and the risk of idiopathic dilated cardiomyopathy in Pakistan[J]. Meta Gene, 2016, 9: 37-41. DOI: 10.1016/j.mgene.2016.03.006.
[4] Belmonte T, Mangas A, Calderon-Dominguez M, et al. Peripheral microRNA panels to guide the diagnosis of familial cardiomyopathy[J]. Transl Res, 2020, 218: 1-15. DOI: 10.1016/j.trsl.2020.01.003.
[5] Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages[J]. Nat Immunol, 2005, 6(11): 1123-32. DOI: 10.1038/ni1254.
[6] Obradovic D, Rommel KP, Blazek S, et al. The potential role of plasma miR-155 and miR-206 as circulatory biomarkers in inflammatory cardiomyopathy[J]. ESC Heart Fail, 2021, 8(3):1850-1860. DOI: 10.1002/ehf2.13304.
[7] Gil-Cruz C, Perez-Shibayama C, De Martin A, et al. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy[J]. Science, 2019, 366(6467): 881-886. DOI: 10.1126/science.aav3487.
[8] Neves EGA, Koh CC, Souza-Silva TG, et al. T-cell subpopulations exhibit distinct recruitment potential, immunoregulatory profile and functional characteristics in chagas versus idiopathic dilated cardiomyopathies[J]. Front Cardiovasc Med, 2022, 9: 787423. DOI: 10.3389/fcvm.2022.787423.
[9] Wei L. Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosis[J]. Exp Mol Pathol, 2011, 90(1): 74-78. DOI: 10.1016/j.yexmp.2010.10.004.
[10] Aleshcheva G, Baumeier C, Harms D, et al. MicroRNAs as novel biomarkers and potential therapeutic options for inflammatory cardiomyopathy[J]. 2023, 10(6): 3410-3418. DOI: 10.1002/ehf2.14523.
[11] Danaii S, Shiri S, Dolati S, et al. The association between inflammatory cytokines and miRNAs with slow coronary flow phenomenon[J]. Iran J Allergy Asthma Immunol, 2020, 19(1): 56-64. DOI: 10.18502/ijaai.v19i1.2418.
|